Association and Haplotype Analysis of the PON1, ITGB3 and CYP3A4 Genes, Strong Candidates for Familial Coronary Artery Disease Susceptibility

Öz

Objective: Genetic predisposition is very common among the patients with coronary artery disease (CAD), a complex and multifactorial disease. Our objective was to determine the possible association between the most remarkable functional variants in the paraoxonase 1(PON1), cytochrome P450 3A4 (CYP3A4), integrin subunit beta 3 (ITGB3) genes and familial CAD. Materials and Methods: We included 117 patients diagnosed with familial CAD and 99 healthy subjects with no family history of CAD. PON1 Q192R, PON1 L55M, CYP3A4*1G and ITGB3 L33P single nucleotide polymorphisms were genotyped using the Sequenom MassARRAY system. Results: Comparison of genotype and allele frequencies in inheritance models of polymorphisms between the patient and control groups did not reveal any significant findings related to CAD. Stratified analysis by gender did also not display any association both in females and males. There was no significant difference in the frequencies of the haplotypes of the PON1 Q192R and L55M polymorphisms between the groups. Conclusions: Our findings confirmed previous studies that did not consider PON1, CYP3A4 and ITGB3 genes as risk loci. The fact that our study was conducted only in patients with familial CAD shows the originality and importance of our results.

Anahtar Kelimeler

• CYP3A4
• familial coronary artery disease
• PON1
• ITGB3

Ailesel Koroner Arter Hastalığına Yatkınlıkta Güçlü Adaylar PON1, ITGB3 ve CYP3A4 Genlerinin Hastalıkla İlişkisi ve Haplotip Analizi

Öz

Amaç: Kompleks ve multifaktöriyel bir hastalık olan koroner arter hastalığında (KAH) genetik yatkınlık çok yaygındır. Amacımız; paraoksonaz 1(PON1), sitokrom P450 3A4 (CYP3A4), integrin subunit beta 3 (ITGB3) genlerindeki en dikkat çekici fonksiyonel varyantlar ile ailesel KAH arasındaki olası ilişkiyi belirlemekti. Materyal ve Metot: Çalışmamıza ailesel KAH tanısı almış 117 hasta ile ailesinde KAH öyküsü olmayan 99 sağlıklı bireyi dahil ettik. PON1 Q192R, PON1 L55M, CYP3A4*1G ve ITGB3 L33P tek nükleotid polimorfizmleri Sequenom MassARRAY sistemi kullanılarak genotiplendirildi. Bulgular: Polimorfizmlerin kalıtım modellerindeki genotip ve allel frekanslarının hasta ve kontrol grupları arasında karşılaştırılması KAH ile ilişkili anlamlı bir bulgu ortaya çıkarmadı. Cinsiyete göre tabakalı analiz yöntemi de hem kadınlarda hem de erkeklerde herhangi bir ilişki göstermedi. PON1 Q192R ve L55M polimorfizmlerinin haplotip frekansları hasta ve kontrol grupları arasında analiz edildiğinde ise yine anlamlı bir fark yoktu. Sonuç: Bulgularımız, PON1, CYP3A4 ve ITGB3 genlerini risk lokusları olarak kabul etmeyen önceki çalışmaları doğrulamış oldu. Çalışmamızın sadece ailesel KAH hastalarında yapılmış olması, sonuçlarımızın özgünlüğünü ve önemini göstermektedir.

Anahtar Kelimeler

• Ailesel koroner arter hastalığı
• CYP3A4
• PON1
• ITGB3

Kaynakça

1. 1. Roberts R, Stewart AF. Genes and coronary artery disease: where are we? J Am Coll Cardiol. 2012;60(18):1715-1721. doi:10.1016/j.jacc.2011.12.062
2. 2. Kessler T, Schunkert H. Coronary artery disease genetics enlightened by Genome-Wide Association Studies. JACC Basic Transl Sci. 2021;6(7):610-623. doi:10.1016/j.jacbts.2021.04.001
3. 3. Taskiran P, Cam SF, Sekuri C, et al. The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. Turk Kardiyol Dern Ars. 2009;37(7):473-478.
4. 4. Elbekai RH, El-Kadi AO. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther. 2006;112(2):564-587. doi:10.1016/j.pharmthera.2005.05.011
5. 5. Minamiyama Y, Takemura S, Akiyama T, et al. Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 1999;452(3):165-169. doi:10.1016/s0014-5793(99)00612-2
6. 6. He BX, Shi L, Qiu J, et al. A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. Basic Clin Pharmacol Toxicol. 2011;108(3):208-213. doi:10.1111/j.1742-7843.2010.00657.x
7. 7. Kucharska-Newton AM, Monda KL, Campbell S, et al. Association of the platelet GPIIb/IIIa polymorphism with atherosclerotic plaque morphology: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2011;216(1):151-156. doi:10.1016/j.atherosclerosis.2011.01.038
8. 8. Price WH, Morris SW, Kitchin AH, et al. DNA restriction fragment length polymorphisms as markers of familial coronary heart disease. Lancet. 1989;1(8652):1407-1411. doi:10.1016/s0140-6736(89)90123-2

9. 9. Rowland A, Mangoni AA. Cytochrome P450 and ischemic heart disease: current concepts and future directions. Expert Opin Drug Metab Toxicol. 2014;10(2):191-213. doi:10.1517/17425255.2014.859675
10. 10. McPherson R, Tybjaerg-Hansen A. Genetics of coronary artery disease. Circ Res. 2016;118(4):564-578. doi:10.1161/CIRCRESAHA.115.306566
11. 11. Abello D, Sancho E, Camps J, Joven J. Exploring the role of paraoxonases in the pathogenesis of coronary artery disease: a systematic review. Int J Mol Sci. 2014;15(11):20997-21010. doi:10.3390/ijms151120997
12. 12. Liu T, Zhang X, Zhang J, et al. Association between PON1 rs662 polymorphism and coronary artery disease. Eur J Clin Nutr. 2014;68(9):1029-1035. doi:10.1038/ejcn.2014.105
13. 13. Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology. 2010;61(2):157-165. doi:10.1177/0003319709351258
14. 14. Lakshmy R, Ahmad D, Abraham RA, et al. Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infarction & association with oxidized low density lipoprotein. Indian J Med Res. 2010;131:522-529.
15. 15. Regieli JJ, Jukema JW, Doevendans PA, et al. Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J Am Coll Cardiol. 2009;54(14):1238-1245. doi:10.1016/j.jacc.2009.05.061
16. 16. Wang X, Fan Z, Huang J, et al. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol. 2003;23(2):328-334. doi:10.1161/01.atv.0000051702.38086.c1
17. 17. Oliveira SA, Mansur AP, Ribeiro CC, Ramires JA, Annichino-Bizzacchi JM. PON1 M/L55 mutation protects high-risk patients against coronary artery disease. Int J Cardiol. 2004;94(1):73-77. doi:10.1016/j.ijcard.2003.05.011
18. 18. Robertson KS, Hawe E, Miller GJ, Talmud PJ, Humphries SE, Northwick Park Heart S, II. Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim Biophys Acta. 2003;1639(3):203-212. doi:10.1016/j.bbadis.2003.09.008
19. 19. Aynacioglu AS, Kepekci Y. The human paraoxonase Gln-Arg192 (Q/R) polymorphism in Turkish patients with coronary artery disease. International Journal of Cardiology. 2000;74(1):33-37. doi:0.1016/S0167-5273(00)00242-4
20. 20. Ozkok E, Aydin M, Babalik E, Ozbek Z, Ince N, Kara I. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients. Med Sci Monit. 2008;14(10):CR536-542.
21. 21. Sayin Kocakap DB, Dogru MT, Simsek V, et al. The association of paraoxonase 1 gene L55M polymorphism with the extent and severity of coronary artery disease in the Turkish population and its dependence on gender. Anatol J Cardiol. 2016;16(3):175-182. doi:10.5152/akd.2015.6010
22. 22. Paszek E, Godlewski J, Wolkow P, et al. Paraoxonase 2 C311S single nucleotide polymorphism is associated with type C lesions in coronary atherosclerosis. Clin Biochem. 2022;105-106:64-69. doi:10.1016/j.clinbiochem.2022.04.009
23. 23. Ashiq S, Ashiq K. The role of paraoxonase 1 (PON1) gene polymorphisms in coronary artery disease: A systematic review and meta-analysis. Biochem Genet. 2021;59(4):919-939. doi: 10.1007/s10528-021-10043-0.
24. 24. Kasarla SS, Garikapati V, Kumar Y, Dodoala S. Interplay of vitamin D and CYP3A4 polymorphisms in endocrine disorders and cancer. Endocrinol Metab (Seoul). 2022;37(3):392-407. doi:10.3803/EnM.2021.1349
25. 25. Balashanmugam MV, Shivanandappa TB, Nagarethinam S, Vastrad B, Vastrad C. Analysis of differentially expressed genes in coronary artery disease by integrated microarray analysis. Biomolecules. 2019;10(1):35. doi: 10.3390/biom10010035
26. 26. Verdoia M, Cassetti E, Schaffer A, Di Giovine G, De Luca G. Platelet glycoprotein IIIa Leu33Pro gene polymorphism and coronary artery disease: A meta-analysis of cohort studies. Platelets. 2015;26(6):530-535. doi:10.3109/09537104.2014.948839
27. 27. Verdoia M, Cassetti E, Schaffer A, et al. Relationship between glycoprotein IIIa platelet receptor gene polymorphism and coronary artery disease. Angiology. 2015;66(1):79-85. doi:10.1177/0003319714524296
28. 28. Floyd CN, Mustafa A, Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis. PLoS One. 2014;9(7):e101518. doi:10.1371/journal.pone.0101518
29. 29. Elsidege Ali LA, Mahdi Hassan F. Association of platelet integrin platelet integrin αIIbβ3 polymorphisms with atherosclerotic coronary heart disease in Sudanese patients. Pak J Biol Sci. 2019;22(7):335-341. doi:10.3923/pjbs.2019.335.341
30. 30. Malakootikhah F, Naghavi H, Firouzabadi N, et al. Association of human platelet alloantigens encoding gene polymorphisms with the risk of coronary artery disease in Iranian patients. BMC Cardiovasc Disord. 2021;21(68). doi:10.1186/s12872-021-01892-z